
Release date: 2026-01-06 10:27:01 Article From: Lucius Laos Recommended: 102
Treat non-small cell lung cancer, medullary thyroid carcinoma, and thyroid cancer caused by RET gene mutations.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Lucius Pharmaceuticals (Lao) Co., Ltd is a Lao pharmaceutical company established in 2020, headquart···【more】
Recommended:[list:visits]2026-30-06
The Lao generic pharmaceutical industry has developed rapidly in recent years, attracting increasing···【more】
Recommended:[list:visits]2026-29-06
Laos; pharmaceutical industry is relatively limited in scale, and domestic drug supply has long reli···【more】
Recommended:[list:visits]2026-26-06
MONDAY, June 15, 2026 — A study published online June 8 in Nature Medicine has found that apitegroma···【more】
Recommended:[list:visits]2026-24-06
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended:[list:visits]2026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:[list:visits]2025-15-12

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643